about
CYP2B6 gene single nucleotide polymorphisms and leukemia susceptibilityGenetic variation in metabolic genes, occupational solvent exposure, and risk of non-hodgkin lymphomaSignificant change of cytochrome P450s activities in patients with hepatocellular carcinomaModulation of cytochrome P450 metabolism and transport across intestinal epithelial barrier by ginger biophenolicsTRAIL-Based High Throughput Screening Reveals a Link between TRAIL-Mediated Apoptosis and Glutathione Reductase, a Key Component of Oxidative Stress ResponseProtective Effects of Essential Oils as Natural Antioxidants against Hepatotoxicity Induced by Cyclophosphamide in MiceNecrosis, and then stress induced necrosis-like cell death, but not apoptosis, should be the preferred cell death mode for chemotherapy: clearance of a few misconceptionsSmoking, the xenobiotic pathway, and clubfootIntegrated structure- and ligand-based in silico approach to predict inhibition of cytochrome P450 2D6.Identification of functional modules that correlate with phenotypic difference: the influence of network topology.Eureka-DMA: an easy-to-operate graphical user interface for fast comprehensive investigation and analysis of DNA microarray data.Discovering gene re-ranking efficiency and conserved gene-gene relationships derived from gene co-expression network analysis on breast cancer data.MspI and Ile462Val polymorphisms in CYP1A1 and overall cancer risk: a meta-analysisDifferential expression of cytochrome P450 enzymes in normal and tumor tissues from childhood rhabdomyosarcoma.Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1 and colorectal cancer riskAccurate DNA fragment sizing by capillary electrophoresis with laser-induced fluorescence array for detection of sequence specificity of DNA damageSpectra and kinetic studies of the compound I derivative of cytochrome P450 119.Kinetics of oxidation of benzphetamine by compounds I of cytochrome P450 2B4 and its mutants.Quantitative production of compound I from a cytochrome P450 enzyme at low temperatures. Kinetics, activation parameters, and kinetic isotope effects for oxidation of benzyl alcohol.Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer.The Impact of CYP2D6 Genotyping on Tamoxifen TreatmentEffect of Naringenin, Quercetin, and Sesamin on Xenobiotica-Metabolizing CYP1A and CYP3A in Mice Offspring after Maternal Exposure to Persistent Organic Pollutants.Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance.The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment.CYP genes in osteosarcoma: Their role in tumorigenesis, pulmonary metastatic microenvironment and treatment response.Far beyond the usual biomarkers in breast cancer: a review.Potentially functional variants of PLCE1 identified by GWASs contribute to gastric adenocarcinoma susceptibility in an eastern Chinese populationGenetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function.A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice.Drug resistance in cancer: an overview.Expression of CYP2W1 in colon tumors: regulation by gene methylation.Frequency and prognostic significant of CYP3A4-A-290G polymorphism in acute myeloid leukemiaPharmacogenetics and pharmacogenomics of anticancer agents.Antiproliferative effect of gynura procumbens (lour.) Merr. Leaves etanolic extract on 7,12-dimethylbenz(a)antracene induced male rat liver.Niche-dependent gene expression profile of intratumoral heterogeneous ovarian cancer stem cell populations.Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?Xenobiotic-metabolizing gene variants, pesticide use, and the risk of prostate cancer.Early growth response 1 loops the CYP2B6 promoter for synergistic activation by the distal and proximal nuclear receptors CAR and HNF4alphaHigh-throughput lipidomic analysis of fatty acid derived eicosanoids and N-acylethanolaminesPart 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.
P2860
Q28294323-2DFB405B-1592-46FD-BFF4-02953BA3B447Q28386043-D9BFFBCA-90B7-4735-AC49-8593560A248EQ28468624-A12ACD37-BBD4-412D-BDAC-E518C5DCE999Q28543201-023436A3-66D6-4E72-8777-DBE9D2320232Q28548386-C3885D02-19D7-4C81-B329-054C878C12DEQ28553094-92911908-546E-4BD0-9909-3FF5D4521071Q28652643-ABE33300-A651-41F9-8717-7C644FFDCE5CQ28672873-BA65A03C-8BEA-47BC-BFEF-01CA759076D8Q30378479-13DBDDA0-8594-4C42-A485-77F19FD04731Q30494575-8504FD79-63D6-4D16-9F49-B68C04314A97Q30763197-3520624F-5B77-4F2E-AD14-81D17F1B1F4FQ31047698-A0B5A933-1D3B-416E-8A1B-5A282B4B6014Q31147198-BA251AD1-E61D-4D3E-825A-0558189AAF66Q31155554-3EA79CC6-BBB7-4FA0-A085-5DE1B6B86494Q33290134-DE1CCE54-9386-4F38-8D5B-4B12B6E87DFFQ33319267-D9803110-D831-45B7-A891-C80DE6980816Q33369172-77495211-9166-4993-9B6C-4904E8EC26BDQ33408246-803B7EB0-BA12-4B82-AFAE-03FB7BDDBE7EQ33477562-3BC13001-DAF9-42AD-8794-E4E49DA877C6Q33591401-48343543-0910-4318-9A0B-1DD6A78B5DBDQ33664433-8017180B-2203-459B-B1C0-A2F482AC5C67Q33711183-4CB76821-92EB-4CF1-8FCA-2E336B4332B2Q33755300-A909792F-1279-448A-926A-95E3721DB3E8Q33769429-2EA33ADC-4A44-46CB-AA60-5DAB9C2E6124Q33888862-6527E552-6A72-40A2-991F-0EDA1D8A3C7CQ33935217-A6C6482B-AB58-4DFC-A7BE-B399FA5BD286Q34193026-5069B6EE-54F5-4116-9273-0AD90A9C96F0Q34273354-9AF12907-AF98-42CE-8487-012C88C97CA2Q34365909-E58B30BF-CF6C-4527-A065-F9A5E80FABC9Q34437369-9E77D77C-338E-4FED-AD4C-8D4123957ECDQ34708842-584E4CA9-E757-4FAC-830F-40301ABD8453Q34951945-6E5D1691-3BE2-4489-A688-400F47EFCBD7Q35030489-DDA90926-87E7-4739-AA47-533039379C19Q35061612-F8F4AE2F-42E4-44CC-A2A6-94893A0AA9A7Q35073159-FD246706-ED1F-4922-A894-02F8BB8B0CDDQ35097430-A70EE1E1-DA2E-4FFE-8334-0950BCAB4A76Q35211213-8AD04667-3199-4F5A-BF85-8A42A4C2067BQ35228636-02F9EA77-C772-47A0-9D3C-21B250685B34Q35490988-33FA1344-18ED-4F93-A6FE-17A9CF9467A5Q35584977-029BF932-23E7-468E-93A3-77328BA3528D
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Cytochrome P450 pharmacogenetics and cancer.
@ast
Cytochrome P450 pharmacogenetics and cancer.
@en
type
label
Cytochrome P450 pharmacogenetics and cancer.
@ast
Cytochrome P450 pharmacogenetics and cancer.
@en
prefLabel
Cytochrome P450 pharmacogenetics and cancer.
@ast
Cytochrome P450 pharmacogenetics and cancer.
@en
P356
P1433
P1476
Cytochrome P450 pharmacogenetics and cancer
@en
P2093
Ingelman-Sundberg M
P2888
P304
P356
10.1038/SJ.ONC.1209377
P407
P577
2006-03-01T00:00:00Z